Business
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain Neurologists/epileptologists Dr. Imad Najm of the
About this update from Ovid Therapeutics Inc.
[{"type":"text","content":"Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the Brain\nNeurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contribute expertise in neurophysiology, hyperexcitability and network effectsThe SAB will advise on the potential application of Ovid’s compounds to broader disorders in which they may offer therapeutic promise, including brain conditions caused by hyperexcitability, neurovascular and neuro-inflammatory dysfunction NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, announced it has significantly expanded its SAB with the appointment of renowned neurologists, neuroscientists, and epileptologists. The new SAB members were appointed to advise Ovid on the potential application of its unique pipeline programs and mechanisms of action to broader areas of neurology in which they may offer therapeutic promise. Specifically, advancements over the last year in Ovid’s Rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor and potassium chloride co-transporter 2 (KCC2) direct activator libraries suggest that these mechanisms may have a fundamental role in modifying intractable disorders of the brain, including conditions caused by hyperexcitability, neurovascular dysfunction and neuroinflammation. The SAB is chaired by Professor Robert Langer, who convened the first meeting of the expanded SAB at Massachusetts Institute of Technology (MIT) in July 2024. Initial areas of focus for the SAB are the translation and clinical development strategies associated with the ROCK2 inhibition and KCC2 direct activator portfolio, which contain multiple compounds and formulation opportunities. “I challenge every team and company that I support to answer big questions that will help patients. Neuroscience is a particularly challenging area in scale and complexity; I believe that Ovid is positioned to ...